If confirmed, etiology-based therapeutic strategies can be tested by targeting multiple signaling steps ranging from blocking the release of Hsp70 and Hsp90 by cancer cells, neutralizing the circulating Hsp70 and Hsp90, to inhibiting the activation of TLR4 or its downstream effectors p38β MAPK and p300 with pharmacological agents. This evidence concerns the gene MAPK11 and cancer.